Genprex shares are trading higher after the company presented preclinical data on Reqorsa Gene Therapy, Mesothelioma, and Glioblastoma at the 2024 EORTC-NCI-AACR Symposium.
Portfolio Pulse from Benzinga Newsdesk
Genprex shares rose following the presentation of preclinical data on Reqorsa Gene Therapy, Mesothelioma, and Glioblastoma at the 2024 EORTC-NCI-AACR Symposium.
October 28, 2024 | 4:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genprex shares increased after presenting promising preclinical data on Reqorsa Gene Therapy, Mesothelioma, and Glioblastoma at a major symposium.
The presentation of promising preclinical data at a significant symposium likely boosted investor confidence in Genprex's future prospects, leading to a rise in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100